aspirin

Overview

Aspirin (acetylsalicylic acid) irreversibly inhibits cyclooxygenase enzymes (COX-1/PTGS1, COX-2/PTGS2), reducing prostaglandin synthesis. In oncology it is investigated primarily as a chemopreventive agent in colorectal cancer, where PIK3CA-mutant tumors have shown differential benefit in retrospective analyses.

Evidence in the corpus

• PIK3CA mutations may predict benefit from aspirin therapy in colorectal cancer (COADREAD); the claim is cited in the context of PI3K-pathway heterogeneity between primary and metastatic lesions, noting that targeted sequencing panels should capture PIK3CA status to guide chemopreventive strategies (Domingo et al. JCO 2013 referenced) PMID:25164765

Resistance mechanisms

None yet recorded.

Cancer types (linked)

• COADREAD — chemopreventive context; PIK3CA-mutant CRC subtype

Sources

• PMID:25164765

This page was processed by entity-page-writer on 2026-05-11.